Concomitant PPIs and capecitabine-based chemoradiotherapy in rectal cancer

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a recent paper by M. Bridoux et al. published in ESMO GI Oncology:

“Concomitant PPI and capecitabine-based CRT in rectal cancer (data from PRODIGE-23):

• No statistical significant association in survival and pathological response
• 38 patients in PPI group, numerically worse survival tendency.”

“Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial”

Authors: M. Bridoux, E. Aymes, T. Conroy, S. Gourgou, A. Carnot, C. Borg, M.-C. Le Deley, A. Turpin.

More posts featuring Erman Akkus.

Erman Akkus is a medical oncology fellow at Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education at the Medical University of Vienna.